Advertisement
Screener

Keros Therapeutics, Inc. (KROS) Graph

KROS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $22.33M; Operating expenses $30.94M; Income tax $0.00.
  • 2026-03-31: Revenue (m); Research and development $16.10M; Operating expenses $26.24M; Income tax $0.00.
  • 2025-12-31: Revenue (m); Research and development $17.91M*; Operating expenses $29.66M*; Income tax -$1.51M*.
  • 2025-09-30: Revenue (m); Research and development $19.52M; Operating expenses $29.65M; Income tax -$1.42M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

KROS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.License$0.00Service$0.00Service Other$0.00License Revenue$0.00Revenue$0.00Operating expenses$30.94MOperating income-$30.94MOther income, net-$60.00KResearch & development$22.33MPre-tax income-$28.71MIncome tax$0.00Net income-$28.71M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

KROS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$0.00Revenue$0.00Operating expenses$30.94MOperating income-$30.94MOther income, net-$60.00KResearch & development$22.33MPre-tax income-$28.71MIncome tax$0.00Net income-$28.71M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$0.00$22.33M$30.94M$0.00-$28.71M
2026-03-31(m)$16.10M$26.24M$0.00-$23.71M
2025-12-31(m)$17.91M*$29.66M*-$1.51M*-$23.46M*
2025-09-30(m)$19.52M$29.65M-$1.42M-$7.28M
2025-06-30$18.17M$43.50M$57.98M-$2.22M-$30.70M
2025-03-31(m)$48.71M$59.21M$10.04M$148.45M
2024-09-30(m)$49.23M$59.05M$0.00-$52.96M
2024-06-30(m)$40.52M$50.48M$0.00-$45.26M
2024-03-31(m)$38.26M$48.57M$0.00-$43.11M
2023-09-30$8.00K$34.14M$43.29M(m)-$39.44M
2023-06-30$0.00$32.53M$41.34M(m)-$37.51M
2023-03-31$0.00$31.09M$38.87M(m)-$35.80M
2022-09-30$0.00$21.04M$27.98M$0.00-$23.51M
2022-06-30$0.00$23.28M$30.73M$0.00-$27.27M
2022-03-31(m)$18.08M$24.13M$0.00-$24.19M
2021-09-30$0.00$14.83M$20.20M-$38.00K-$20.30M
2021-06-30$100.00K$9.98M$15.64M$0.00-$15.62M
2021-03-31(m)$11.49M$15.77M$50.00K-$15.88M
2020-09-30$0.00$8.39M$11.95M$0.00-$12.04M
2020-06-30$0.00$7.26M$10.91M$0.00-$10.76M
2020-03-31$0.00$8.53M$10.50M-$172.00K-$11.89M
2019-09-30$2.50M$3.85M$4.83M$0.00-$3.55M
2019-06-30$2.50M$4.50M$5.15M$0.00-$2.85M
2019-03-31$2.50M$4.87M$5.36M$0.00-$3.18M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$38.43M$57.18M$0.00-$52.42M
2025-06-30(m)$92.21M$117.19M$7.82M$117.75M
2024-06-30(m)$78.77M$99.04M$0.00-$88.37M
2023-06-30$0.00$63.63M$80.21M(m)-$73.31M
2022-06-30$0.00$41.36M$54.85M$0.00-$51.45M
2021-06-30$100.00K$21.48M$31.41M$50.00K-$31.51M
2020-06-30$0.00$15.79M$21.42M-$172.00K-$22.65M
2019-06-30$5.00M$9.36M$10.51M$0.00-$6.04M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$111.73M$146.84M$6.40M$110.47M
2024-09-30(m)$128.00M$158.09M$0.00-$141.33M
2023-09-30$8.00K$97.77M$123.49M(m)-$112.75M
2022-09-30$0.00$62.40M$82.83M$0.00-$74.96M
2021-09-30$100.00K$36.31M$51.61M$12.00K-$51.80M
2020-09-30$0.00$24.19M$33.37M-$172.00K-$34.69M
2019-09-30$7.50M$13.22M$15.34M$0.00-$9.59M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$129.64M$176.49M$4.88M$87.01M
2024-12-31(m)$173.63M$214.38M$300.00K-$187.35M
2023-12-31$151.00K$135.26M$170.09M$0.00-$152.99M
2022-12-31$0.00$87.27M$114.79M$0.00-$104.68M
2021-12-31$20.10M$55.14M$76.47M$2.01M-$58.74M
2020-12-31$0.00$33.86M$46.66M-$172.00K-$45.36M
2019-12-31$10.00M$17.38M$20.56M$0.00-$12.34M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
NATURES SUNSHINE PRODUCTS INC (NATR)United States$0.228B20.51
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
MACROGENICS INC (MGNX)United States$0.242B-20.11
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73